AQST vs LLY · rev $28.3M vs P/E 39, rev $22.97B
Aquestive Therapeutics Inc (AQST) versus Eli Lilly and Company (LLY) — a side-by-side from cached financials, not a winner call.
Aquestive Therapeutics Inc (AQST) is a drug manufacturers - specialty & generic company listed on US.
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David A. Ricks.
Latest reported AQST revenue for 2026-06-30 was $28.3M. Net income was -$30.9M. Revenue was up 95.7% from 2026-03-31 to 2026-06-30. AQST currently screens at market cap $493.0M.
Latest reported LLY revenue for 2026-06-30 was $22.97B. Net income was $7.09B. Revenue was up 16.0% from 2026-03-31 to 2026-06-30. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
AQST currently screens at market cap $493.0M. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
Not investment advice. Open the AQST and LLY stock pages for the full models.
Not investment advice.